Dr Trevor Phillips, Executive Chairman
Dr Trevor Phillips became a Non-Executive Director of hVIVO plc in June 2017 and Executive Chairman in November 2017. Trevor has over thirty years of experience within the pharmaceutical industry, including extensive international drug development and corporate development responsibilities. He was previously Chief Operations Officer and President of US Operations, as well as a member of the Board, at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focused on airway diseases. Subsequent to joining Vectura in 2010, Trevor played an integral leadership role in the company’s successful development, including the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016.
Prior to joining Vectura, Trevor held the roles of Chief Executive Officer and Chief Operating Officer at Critical Therapeutics, Inc. (now Chiesi USA, Inc.), a US listed specialty pharmaceutical company, where he was involved in setting up commercial partnerships, product in-licensing and out-licensing, managing drug development, commercial product manufacturing and M&A activity. He led the merger of Critical Therapeutics with Cornerstone BioPharma Holdings. He has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.), Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc).
Trevor trained as a microbiologist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986. He was awarded an MBA from Henley Management College in 1997.
Shelley Fraser, Finance Director and Company Secretary
Shelley joined hVIVO June 2016 as VP Finance and was appointed Finance Director and Company Secretary in January 2019. Shelley has over 18 years’ experience in the Pharmaceutical, Biotech and Life Sciences industry operating in service and product offering environments A chartered accountant, she has worked in Asia Pacific and Europe, reporting to US blue chip companies, Merck and Thermo Fisher Scientific . Shelley has more than 15 years as Finance Director with broader responsibilities covering facilities, supply chain, IT and HR.
Tim Sharpington, Chief Operating Officer
Tim joined hVIVO in April 2018 and is Chief Operating Officer. Tim brings to hVIVO more than 25 years’ experience in the life sciences sector with various pharmaceutical, biotechnology and pharmaceutical service companies in Europe and the US. He also brings broad experience in drug development, product licensing, mergers, acquisitions and fundraisings. Tim has held leadership positions at Pfizer, ICON, Sequus, Arakis and Serentis, and his most recent major role was as Executive Vice President Development at Vectura Group Plc, a UK company also focused on airways disease.
Reid Tripp, Executive Vice President, Business Development & Marketing
Reid has more than 25 years of international experience within the life science industry and has an MBA.
Before joining hVIVO, he held senior management business development and marketing positions with various large, mid-sized and small global Clinical Research Organisations where he successfully built and managed sales, marketing, proposals and contracts teams, delivered hundreds of millions in contractual relationships and overall, enhanced customer satisfaction. Reid has also served in a senior management role at a start-up biotechnology company and has held various management positions for a large pharmaceutical company.
Fleur Wood, Executive Vice President, Investor Relations and Communications
Fleur joined hVIVO in April 2018 and is a member of the Leadership Team and Executive Vice President, Investor Relations & Communications. Fleur brings over 20 years’ experience of Investor Relations, communications and capital markets experience gained primarily within the UK Investment Banking industry and the Pharmaceuticals sector. During her career she has brought strategic IR skills to both M&A situations and to companies undergoing growth and change.
Fleur’s previous role was at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focused on airways diseases, where she held positions of Director of Communications and Director of Investor Relations and had an integral role in the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016.